S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Alterity Therapeutics Stock Forecast, Price & News

-0.05 (-6.14%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
507,089 shs
Average Volume
9.90 million shs
Market Capitalization
$17.27 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATHE News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Alterity Therapeutics logo

About Alterity Therapeutics

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The firm focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.


Pre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP…
January 6, 2022 |  markets.businessinsider.com
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report
October 29, 2021 |  finance.yahoo.com
ATHE, NMTR and PXLW among pre among gainers
August 22, 2021 |  seekingalpha.com
99 Biggest Movers From Yesterday
August 6, 2021 |  msn.com
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
July 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.37 million
Book Value
$1.01 per share


Pretax Margin




Free Float
Market Cap
$17.27 million
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

2.16 out of 5 stars

Medical Sector

443rd out of 1,418 stocks

Pharmaceutical Preparations Industry

203rd out of 684 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Alterity Therapeutics (NASDAQ:ATHE) Frequently Asked Questions

Is Alterity Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alterity Therapeutics stock.
View analyst ratings for Alterity Therapeutics
or view top-rated stocks.

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a drop in short interest in the month of December. As of December 15th, there was short interest totaling 405,600 shares, a drop of 32.1% from the November 30th total of 597,000 shares. Based on an average daily volume of 417,700 shares, the days-to-cover ratio is currently 1.0 days.
View Alterity Therapeutics' Short Interest

What price target have analysts set for ATHE?

1 analysts have issued 1 year target prices for Alterity Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Alterity Therapeutics' share price to reach $4.00 in the next year. This suggests a possible upside of 423.6% from the stock's current price.
View analysts' price targets for Alterity Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Alterity Therapeutics' key executives?

Alterity Therapeutics' management team includes the following people:
  • Geoffrey Paul Kempler, Non-Executive Chairman
  • David A. Stamler, Chief Executive Officer
  • Kathryn J. E. Andrews, Chief Financial Officer
  • Phillip Allen Hains, Secretary

What other stocks do shareholders of Alterity Therapeutics own?

What is Alterity Therapeutics' stock symbol?

Alterity Therapeutics trades on the NASDAQ under the ticker symbol "ATHE."

How do I buy shares of Alterity Therapeutics?

Shares of ATHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alterity Therapeutics' stock price today?

One share of ATHE stock can currently be purchased for approximately $0.76.

How much money does Alterity Therapeutics make?

Alterity Therapeutics has a market capitalization of $17.27 million and generates $3.37 million in revenue each year.

How many employees does Alterity Therapeutics have?

Alterity Therapeutics employs 2,021 workers across the globe.

What is Alterity Therapeutics' official website?

The official website for Alterity Therapeutics is www.alteritytherapeutics.com.

Where are Alterity Therapeutics' headquarters?

Alterity Therapeutics is headquartered at LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000.

How can I contact Alterity Therapeutics?

Alterity Therapeutics' mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The company can be reached via phone at (139) 349-4906, via email at [email protected], or via fax at 61-3-9348-0377.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.